Advanced Glycosylation End Product Specific Receptor (AGER) Antibody
260€ (100 µl)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Advanced Glycosylation End Product Specific Receptor (AGER) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx104577
tested applications
WB, IHC
Description
Polyclonal Antibody to AGER (AGER).
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Target: Advanced Glycosylation End Product Specific Receptor (AGER) Immunogen: abx065184 - Recombinant Human AGER (Ile91-Asp274) expressed in E. coli |
| Host | Rabbit |
| Reactivity | Human |
| Recommended Dilution | WB: 0.01-2 µg/ml, IHC: 5-20 µg/ml. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Polyclonal |
| Conjugation | Unconjugated |
| Purification | Purified by antigen-specific affinity chromatography, followed by Protein A affinity chromatography. |
| Size 1 | 100 µl |
| Size 2 | 200 µl |
| Size 3 | 1 ml |
| Form | Liquid |
| Tested Applications | WB, IHC |
| Buffer | PBS, pH7.4, containing 0.02% NaN3, 50% glycerol. |
| Availability | Shipped within 5-7 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | Q15109 |
| Alias | RAGE,SCARJ1,sRAGE |
| Background | Antibody anti-AGER |
| Status | RUO |
| Note | THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION. |
Descripción
AGER, also known as RAGE (Receptor for Advanced Glycation End Products), is a transmembrane receptor belonging to the immunoglobulin superfamily that binds to AGEs and other ligands such as S100 proteins, HMGB1, and amyloid-β. AGER is widely expressed, particularly in the endothelium, lungs, brain, and immune cells, and plays a critical role in inflammatory and oxidative stress signaling. Binding of AGEs to AGER activates downstream pathways, including NF-κB, MAPK, and JAK/STAT, leading to the production of pro-inflammatory cytokines and reactive oxygen species. Overexpression or chronic activation of AGER is associated with diseases such as diabetes complications, atherosclerosis, Alzheimer’s disease, and cancer, where it exacerbates inflammation and tissue damage. AGER is a promising therapeutic target for reducing AGE-mediated pathologies and modulating immune and metabolic dysfunction.
Related Products
Human Advanced Glycosylation End Product Specific Receptor (AGER) Protein
Human Advanced Glycosylation End Product Specific Receptor (AGER) protein is a recombinant protein expressed in E. coli.
Ver Producto